All News

CHICAGO--Donor lymphocyte infusion is proving to be a potent treatment for chronic myelogenous leukemia (CML) patients who relapse after allogeneic bone marrow transplant (BMT). It also may improve the overall outcome of CML patients after transplantation, said William Drobyski, MD, at the sixth annual Malnati Symposium in the Clinical Sciences, sponsored by Northwestern University School of Medicine.

VANCOUVER, BC--CD8+ T cells appear to play a central role in the body's strategy for fighting HIV, particularly in those patients known as long-term non-progressors or long-term survivors who remain well for many years despite being infected with HIV.

BUFFALO, NY--A cognitive remediation program that stresses skills acquisition rather than reiterative practice may improve attention and concentration deficits in cognitively impaired survivors of childhood cancer, Robert W. Butler, PhD, reported at the Fourth International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer.

NEW YORK--AIDS patients are vastly undermedicated for their pain, a new study from Memorial Sloan-Kettering Cancer Center has shown.

NEW YORK--A new resource guide from Cancer Care Inc. details the kinds of information and services that are available around the country for people with cancer.

NEW YORK--Michael Korda, best-selling author and editor-in-chief and vice president of Simon and Schuster, had never heard of PSA until a routine test showed that his was elevated; he had never thought about prostate cancer as something that could happen to him. After all, he was asymptomatic, a "fanatic exerciser," had given up smoking 20 years ago, and ate carefully.

BETHESDA, Md--The increasing commercial interest in developing tests for genetic disorders makes it imperative to come up with guidelines for use of such tests as quickly as possible, Neil Holtzman, MD, MPH, head of the genetic task force assembled by the NIH and DOE, told the National Cancer Advisory Board (NCAB).

VANCOUVER, BC--The discovery in 1994 of a new human herpesvirus associated with Kaposi's sarcoma (KS) brought some order to the previously contentious discussion about causes of the disease in patients with HIV. Researchers at the 11th International Conference on AIDS further nailed human herpesvirus-8 (HHV-8, also known as Kaposi's sarcoma-associated herpesvirus or KSHV) as the culprit in many, if not most, cases of KS (see also, page 1).

NEW YORK--The Leukemia Society of America has launched First Connection, a pilot program for helping newly diagnosed leukemia patients and their families receive counseling and information in the initial hours after diagnosis. Patients will be visited by a specially trained peer volunteer who has gone through a similar experience.

WASHINGTON--President Clinton has announced new restrictions on tobacco advertising and sales intended to cut teenage smoking in half over the next 7 years.

Reducing the prevalence of cigarette smoking among adults to no more than 15% is one of the national health objectives for the year 2000 (objective 3.4). To assess progress toward meeting this objective, the CDC analyzed self-reported information about cigarette smoking among US adults contained in the Year 2000 Objectives Supplement of the 1994 National Health Interview Survey (NHIS-2000). This report summarizes the findings of this analysis, which indicate that, in 1994, 25.5% (48.0 million) of adults were current smokers and that the overall prevalence of current smoking and estimates for sociodemographic subgroups were unchanged from 1993 to 1994.

Scientists searching for molecular clues to cancer have produced a detailed picture showing how a key protein blocks a central promoter of cell growth involved in virtually all human cancers. The discovery sets the stage for developing drugs to mimic the protein, called p27, with the hope of halting the uncontrolled cell division that ultimately leads to the formation of tumors.

Young tobacco farmers, feeling the heat from tobacco imports, increased regulation, and public health concerns, are interested in diversifying their crops, according to a recently completed survey sponsored by The Robert Wood Johnson Foundation (RWJF).

VANCOUVER, BC--How much insulin do you give a patient with diabetes--as much as is required to control blood sugar. "The same is true for opioids and patients with cancer pain, "Richard B. Patt, MD, said at a symposium held in conjunction with the 8th World Congress on Pain. "The only difference is we don't have a blood test to measure a patient's opioid requirement the way we do with insulin."

SAN DIEGO--Because of the new realities of health care, it is time to rethink the concept of traditional oncology units, Jeanne T. Reardon, RN, said at the 8th Annual Cancer Care Symposium sponsored by the Society for Ambulatory Care Professionals and Health Technology Assessment of the American Hospital Association.

The Moran article presents an excellent summary of the malignancies associated with HIV. The diagnosis of an HIV-related malignancy places additional stress on an already compromised immune system. Neoplasms arising in AIDS patients tend to be aggressive, and because of the immunocompromised state of these patients, they are unable to tolerate the side effects of the various modalities used in treatment.

VANCOUVER, BC--Human herpesvirus-8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus or KSHV, appears to be linked to the development not only of Kaposi's sarcoma (KS) but also to a newly identified type of AIDS lymphoma, Alexandra Levine, MD, said at an educational symposium at the 11th International Conference on AIDS.

OWINGS MILLS, Md--"I once worked with an oncologist who would not treat a child the same age as his son. One year it was 10; the next year, 11," said Daniel Timmel, LCSW, of the Medical and Chirurgical Faculty of Maryland (the state medical society). "Defenses are very interesting."

A recent survey of 224 hospitals nationwide, conducted by health-care management consulting firm TriBrook/AM&G, revealed that the number of hospitals pursuing managed-care affiliations is growing quickly, outpacing the growth in mergers and acquisitions.

Researchers at the Howard Hughes Medical Institute at Duke University Medical Center have shown how drugs that stop organ transplant rejection also partially reverse drug resistance in certain cancer cells.

Times change; the pendulum swings. Once, not so many years ago, mainstream health providers and insurers viewed all alternative and complementary practitioners as quacks.

BETHESDA, Md--A clinical education television series--Bench to Bedside--NIH Grand Rounds--is set to debut on January 15, 1997. Once a month, the world's leading clinicians from the various NIH institutes will discuss critical medical topics of the day.

PRINCETON, NJ--Bristol-Myers Squibb Company has received FDA clearance to market Etopophos (etoposide phosphate) for injection, a new water-soluble version of its anticancer drug VePesid (etoposide).

The American Association for Cancer Research (AACR) has announced the availability of its four annual research awards. The Gertrude Elion award, provided through an educational grant from Glaxo Wellcome Oncology, is open to nontenured cancer researchers in clinical, basic, or translational research in the United States and Canada.

VANCOUVER, BC--Expansion of CD4+ cells could help reconstitute the immune system in patients with AIDS. However, this approach has been unfeasible because stimulation of a patient's CD4+ cells to replicate also leads to HIV replication and greater cell death.

Medical College of Wisconsin researchers recently reported on a study linking Helicobacter pylori to precancerous lesions of the stomach. By infecting specially bred mice with H pylori and showing the resulting precancerous changes in their stomachs, the researchers have uncovered an important clue to the origins of stomach cancer. Their results are the closest evidence to date showing that H pylori causes stomach cancer in any animal model.

BOSTON--Previous study results showing that screening mammography is beneficial only in women over age 50 may stem from inappropriate grouping of age-based data rather than an actual change in benefit at age 50, Daniel B. Kopans, MD, and his colleagues assert in a new study.

Cancer is a genetic disease wherein mutations of growth regulatory genes result in abnormal proliferative capacity, recognized clinically as the occurrence of a malignant tumor. Transcription factors govern the expression of genes, be they "housekeeping" or regulatory. These factors organize the first crucial step in establishing the function of the gene, namely, the transcription of information in DNA into messenger RNA (mRNA). Translation of mRNA results in the synthesis of the oncogenic protein. Hence, the design of therapeutic agents targeted at transcription factors regulating the initial flow of "bad" information from "damaged" genes should be the ultimate goal of efforts to develop new weapons in the therapeutic armamentarium of the oncologist and, indeed, the general internist.

elloff and colleagues have been key players in the recent development of chemoprevention strategies--as initiators of their own studies and minders of others. The succinct summary of their approach is of particular value to oncologists, both because it provides a great deal of data on the current state of chemoprevention research itself and because it draws some useful distinctions between chemoprevention and chemotherapy.

The article by Kelloff et al is a useful, comprehensive review of the current strategy underlying the development of clinically useful chemoprevention agents. One important topic that is not addressed in the article is the failure of micronutrients (selected on the basis of favorable epidemiologic finding) when tested as chemopreventive agents in clinical trials. Two examples of this are particularly noteworthy: In two large randomized trials involving heavy current or former smokers, b-carotene supplementation resulted in an increase in lung cancers compared to placebo.[1,2] Also, in two large randomized trials, folic acid supplementation had no effect on the natural history of cervical intraepithelial neoplasia.[3,4]